Literature DB >> 10097072

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.

H Hsu1, D L Lacey, C R Dunstan, I Solovyev, A Colombero, E Timms, H L Tan, G Elliott, M J Kelley, I Sarosi, L Wang, X Z Xia, R Elliott, L Chiu, T Black, S Scully, C Capparelli, S Morony, G Shimamoto, M B Bass, W J Boyle.   

Abstract

A receptor that mediates osteoprotegerin ligand (OPGL)-induced osteoclast differentiation and activation has been identified via genomic analysis of a primary osteoclast precursor cell cDNA library and is identical to the tumor necrosis factor receptor (TNFR) family member RANK. The RANK mRNA was highly expressed by isolated bone marrow-derived osteoclast progenitors and by mature osteoclasts in vivo. Recombinant OPGL binds specifically to RANK expressed by transfected cell lines and purified osteoclast progenitors. Transgenic mice expressing a soluble RANK-Fc fusion protein have severe osteopetrosis because of a reduction in osteoclasts, similar to OPG transgenic mice. Recombinant RANK-Fc binds with high affinity to OPGL in vitro and blocks osteoclast differentiation and activation in vitro and in vivo. Furthermore, polyclonal Ab against the RANK extracellular domain promotes osteoclastogenesis in bone marrow cultures suggesting that RANK activation mediates the effects of OPGL on the osteoclast pathway. These data indicate that OPGL-induced osteoclastogenesis is directly mediated through RANK on osteoclast precursor cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10097072      PMCID: PMC22329          DOI: 10.1073/pnas.96.7.3540

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

2.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

Authors:  N Bucay; I Sarosi; C R Dunstan; S Morony; J Tarpley; C Capparelli; S Scully; H L Tan; W Xu; D L Lacey; W J Boyle; W S Simonet
Journal:  Genes Dev       Date:  1998-05-01       Impact factor: 11.361

3.  Requirement for NF-kappaB in osteoclast and B-cell development.

Authors:  G Franzoso; L Carlson; L Xing; L Poljak; E W Shores; K D Brown; A Leonardi; T Tran; B F Boyce; U Siebenlist
Journal:  Genes Dev       Date:  1997-12-15       Impact factor: 11.361

4.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.

Authors:  H Yasuda; N Shima; N Nakagawa; S I Mochizuki; K Yano; N Fujise; Y Sato; M Goto; K Yamaguchi; M Kuriyama; T Kanno; A Murakami; E Tsuda; T Morinaga; K Higashio
Journal:  Endocrinology       Date:  1998-03       Impact factor: 4.736

5.  Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2.

Authors:  V Iotsova; J Caamaño; J Loy; Y Yang; A Lewin; R Bravo
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

6.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

7.  Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat.

Authors:  M Yamamoto; T Murakami; M Nishikawa; E Tsuda; S Mochizuki; K Higashio; T Akatsu; K Motoyoshi; N Nagata
Journal:  Endocrinology       Date:  1998-09       Impact factor: 4.736

8.  Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase.

Authors:  B G Darnay; V Haridas; J Ni; P A Moore; B B Aggarwal
Journal:  J Biol Chem       Date:  1998-08-07       Impact factor: 5.157

9.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Authors:  D M Anderson; E Maraskovsky; W L Billingsley; W C Dougall; M E Tometsko; E R Roux; M C Teepe; R F DuBose; D Cosman; L Galibert
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

10.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.

Authors:  A Mizuno; N Amizuka; K Irie; A Murakami; N Fujise; T Kanno; Y Sato; N Nakagawa; H Yasuda; S Mochizuki; T Gomibuchi; K Yano; N Shima; N Washida; E Tsuda; T Morinaga; K Higashio; H Ozawa
Journal:  Biochem Biophys Res Commun       Date:  1998-06-29       Impact factor: 3.575

View more
  383 in total

Review 1.  Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.

Authors:  B G Darnay; B B Aggarwal
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  RANK is essential for osteoclast and lymph node development.

Authors:  W C Dougall; M Glaccum; K Charrier; K Rohrbach; K Brasel; T De Smedt; E Daro; J Smith; M E Tometsko; C R Maliszewski; A Armstrong; V Shen; S Bain; D Cosman; D Anderson; P J Morrissey; J J Peschon; J Schuh
Journal:  Genes Dev       Date:  1999-09-15       Impact factor: 11.361

3.  RANKing the importance of measles virus in Paget's disease.

Authors:  F P Ross
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

4.  Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha.

Authors:  S Cenci; M N Weitzmann; C Roggia; N Namba; D Novack; J Woodring; R Pacifici
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 5.  Regulation of osteoclast formation and function.

Authors:  L T Duong; G A Rodan
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 6.  Osteoprotegerin.

Authors:  U Feige
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

7.  IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB.

Authors:  Y Abu-Amer
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

8.  Role of TNF alpha and PLF in bone remodeling in a rat model of repetitive reaching and grasping.

Authors:  Shobha Rani; Mary F Barbe; Ann E Barr; Judith Litivn
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

9.  Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Authors:  D L Lacey; H L Tan; J Lu; S Kaufman; G Van; W Qiu; A Rattan; S Scully; F Fletcher; T Juan; M Kelley; T L Burgess; W J Boyle; A J Polverino
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

10.  Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis.

Authors:  Ji H Kim; Subash C Gupta; Byoungduck Park; Vivek R Yadav; Bharat B Aggarwal
Journal:  Mol Nutr Food Res       Date:  2011-12-07       Impact factor: 5.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.